Advice

following a full submission

everolimus (Afinitor®) is accepted for use within NHS Scotland.

Indication under review: Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin (pNET) in adults with progressive disease.

Everolimus was superior to placebo in prolonging progression-free survival in adults with progressive, advanced pNET who were receiving best supportive care.

Download detailed advice236KB (PDF)

Download

Medicine details

Medicine name:
everolimus (Afinitor)
SMC ID:
777/12
Indication:
Treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin (pNET) in adults with progressive disease.
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Superseded
Date advice published
14 May 2012
Additional notes

NICE MTA Advice:  SMC Advice is superseded by National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal (MTA)